| Field Name |
Format |
Description |
| PATIENT | Character or Numeric | *Required Code to identify patient (Cohort Patient ID) |
| MED_ID | Character
See Code ListMED_ID | Code | Definition | | A10A | Insulin or derivatives hereof | | A10B | Oral antidiabetic agents | | A11CC | vitamin D | | A14A | Anabolic steroids/appetite stimulants | | B01AC | Anti-platelets | | C-HYP | Other anti-hypertensive agents [C02, C03, C04, C07, C08] | | C09 | ACE inhibitors | | C10 | Lipid-lowering agents | | G02CA | Tocolysis | | H02 | Corticosteroids | | J01 | Antibiotics | | J01AA08 | Minocycline (MINOCIN) | | J01EA01 | Trimethoprim (MONOTRIM, NOPIL) | | J01EC02 | Sulfadiazine | | J01EE | Cotrimoxazole - Comb. of sulfonamides and trimethoprim (BACTRIM, EUSAPRIM, NOPIL) | | J01EE01 | Sulfamethoxazole and trimethoprim (Bactrim) | | J01EE03 | Sulfametrole and trimethoprim - Cosoltrime (MADERAN) | | J01FA09 | Clarithromycine (KLACID) | | J01FA10 | Azithomycine (ZITHROMAX) | | J01FF01 | Clindamycine (DALACIN) | | J01GA01 | streptomycin | | J01GB06 | Amikacine (AMIKINE) | | J01MA02 | Ciprofloxacine (CIPROXINE, CILOXAN) | | J01MA12 | Levofloxacin (TAVANIC) | | J01MA14 | Moxifloxacin | | J01RA02 | Cosoltrime (MADERAN) | | J02AA01 | Amphotericin B (FUNGIZON) | | J02AB | Imidazoles (DAKTARIN, NIZORAL, PEVARYL, etc.) | | J02AB02 | Ketoconazole | | J02AC01 | Fluconazole (DIFLUCAN) | | J02AC02 | Itraconazole (SPORANOX) | | J02AC03 | Voriconazole | | J02AC04 | Posaconazole | | J02AC05 | Isavuconazole | | J02AX01 | Flucytosine | | J02AX04 | caspofungin | | J04A | Drugs for treatment of tuberculosis | | J04AB02 | Rifampin (RIMATICIN) | | J04AB04 | Rifabutin (MYCOBUTIN) | | J04AB05 | Rifapentine (Priftin) | | J04AC01 | Isoniazide (RIMIFON) | | J04AK01 | Pyrazinamide (PYRAZINAMID) | | J04AK02 | Ethambutol (EMB, MYAMBUTOL) | | J04AM02 | rifampicin and isoniazid | | J04AM03 | ethambutol and isoniazid | | J04AM05 | rifampicin, pyrazinamide and isoniazid (RIFATER) | | J04AM06 | rifampicin, pyrazinamide, ethambutol and isoniazid | | J04AM07 | rifampicin, ethambutol and isoniazid | | J04AK | Other drugs for treatment of tuberculosis (not specified elsewhere in code list) | | J04BA01 | Clofazimine (LAMPREN) | | J04BA02 | Dapsone | | J05AB01 | Aciclovir (ZIVORAX) | | J05AB04 | Ribavirin | | J05AB06 | Ganciclovir (CYMEVENE) | | J05AB09 | Famciclovir | | J05AB11 | Valaciclovir (VALTEX) | | J05AB12 | Cidofovir (VISTIDE) | | J05AB15 | Valganciclovir | | J05AD01 | Foscarnet (FOSCAVIR) | | J05AE11 | Telaprevir (INCIVEK, INCIVO) | | J05AE12 | Boceprevir (VICTRELIS) | | J05AE13 | Faldaprevir | | J05AE14 | Simeprevir | | J05AE15 | Asunaprevir | | J05AF08 | Adefovir (PREVEON) | | J05AF10 | Entecavir | | J05AF11 | Telbivudine | | J05AF12 | Clevudine | | J05AR-DAAS | Daclatasvir/Asunaprevir | | J05AX GRAZ-ELB | Grazoprevir/Elbasvir | | J05AX14 | Daclatasvir | | J05AX15 | Sofosbuvir | | J05AX16 | Dasabuvir | | J05AX65 | Ledipasvir/Sofosbuvir | | J05AX67 | Ombitasvir, paritaprevir(ABT-450) and ritonavir | | J07BM0 | HPV Vaccine | | J07BM01 | HPV Vaccine (types 6, 11, 16, 18) | | J07BM02 | HPV Vaccine (types 16, 18) | | J07BM03 | HPV Vaccine (types 6, 11, 16, 18, 31, 33, 45, 52, 58) | | L01AA01 | Cyclophosphamide (ENDOXAN) | | L01AD02 | CCNU (LOMUSTINE) | | L01AX04 | Dacabazine (DTIC - Dome) | | L01BA01 | Methotrexate | | L01CA01 | Vinblastin (VELBE) | | L01CA02 | Oncovin (VINCRISTINE) | | L01CB01 | Etoposide (VEPESIDE, EXITOP 100) | | L01DB01 | Doxorubicine, Adriamycine (DOXIL, CAELYX, ADRIBLASTIN) | | L01DC01 | Bleomycine | | L01XB01 | Procarbazine (NATULAN) | | L03AA02 | G-CSF/Filgastrim (NEUPOGEN) | | L03AB | Interferons | | L03AB-AL2 | Peginterferon alfa-2a/alfa-2b (PEGINTRON, PEGASYS) | | L03AB10 | Peginterferon alfa-2b (PEGINTRON) | | L03AB11 | Peginterferon alfa-2a (PEGASYS) | | L03AC-IL2 | Interleukin 2 (PROLEUKIN) | | M05BA | Bisphosphonate | | N03A | Antiepileptics | | N05A | Antipsychotics | | N05CD | Benzodiazepine derivatives | | N05CF | Benzodiazepine related drugs | | N06A | Antidepressant | | N07BC | Other drugs used in opioid dependence | | N07BC01 | Buprenorphine | | N07BC02 | Methadone | | N07BC03 | Levacetylmethadol | | N07BC04 | Lofexidine | | N07BC51 | Buprenorphine, combinations | | P01AX06 | Atovaquone (WELLVONE, MEPRONE) | | P01BA03 | Primaquine | | P01BD01 | Pyrimethamine (DARAPRIM) | | P01BD51 | Pyrimethamine/Sulfadoxine (FANSIDAR) | | P01CX01 | Pentamidine aerosol (PENTACARNET) | | V03AB15 | Naloxone | | V03AF03 | Folinate of calcium (LEUCOVORINE) |
| *Required ATC Code for drug See ATC code list |
| MED_SD | YYYY-MM-DD | *Required Date of initiation of drug |
| MED_SD_A | Character < = Before this date
D = Exact to the date
M = Exact to the month
Y = Exact to the year
> = After the date
U = Unknown
| Date approximation for MED_SD |
| MED_ED | YYYY-MM-DD | |
| MED_ED_A | Character < = Before this date
D = Exact to the date
M = Exact to the month
Y = Exact to the year
> = After the date
U = Unknown
| Date approximation for MED_ED |
| MED_RS | Character
See Code ListMED_RS | Code | Definition | | 1 | Treatment failure (i.e. virological, immunological, and /or clinical failure) | | 1.1 | Virological failure | | 1.2 | Partial virological failure | | 1.3 | Immunological failure - CD4 drop | | 1.4 | Clinical progression | | 1.5 | Resistance (based on test result) | | 2 | Abnormal fat redistribution | | 3 | Concern of cardiovascular disease | | 3.1 | Dyslipidaemia | | 3.2 | Cardiovascular disease | | 4 | Hypersensitivity reaction | | 5 | Toxicity, predominantly from abdomen/G-I tract | | 5.1 | Toxicity - GI tract | | 5.2 | Toxicity - Liver | | 5.3 | Toxicity - Pancreas | | 6 | Toxicity, predominantly from nervous system | | 6.1 | Toxicity - peripheral neuropathy | | 6.2 | Toxicity - neuropsychiatric | | 6.3 | Toxicity - headache | | 7 | Toxicity, predominantly from kidneys | | 8 | Toxicity, predominantly from endocrine system | | 8.1 | Diabetes | | 9 | Haematological toxicity (anemia, etc.) | | 10 | Hyperlactataemia/lactic acidosis | | 11 | Bone toxicity | | 15 | Social contra-indication | | 16 | Contra-indication unspecified | | 16.8 | Contra-indication expired | | 16.9 | Contra-indication - other | | 17 | MTCT regimen completed | | 70 | Pregnancy - toxicity concerns (during pregnancy) | | 75 | Pregnancy - switch to a more appropriate regimen for PMTCT | | 88 | Death | | 90 | Side effect - any of the above not mentioned | | 90.1 | Comorbidity | | 91 | Toxicity - other (not mentioned above) | | 91.1 | Toxicity - unspecified | | 92 | More effective treatment available | | 92.1 | Simplified treatment available | | 92.2 | Treatment too complex | | 92.3 | Drug interaction | | 92.31 | Drug interaction - commencing TB/BCG treatment | | 92.32 | Drug interaction - ended TB/BCG treatment | | 92.33 | Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available) | | 92.4 | Protocol change | | 92.5 | Regular treatment termination (used in tblMED e.g. for DAAs against HCV, antibiotics) | | 92.6 | End of empiric therapy | | 92.9 | Change in treatment not due to side-effects, failure, poor adherence or contra-indication | | 92.91 | Change to a generic drug | | 92.92 | Change to branded drug | | 93 | Structured Treatment Interruption (STI) | | 93.1 | Structured Treatment Interruption (STI)-at high CD4 | | 94 | Patient's wish/ decision, not specified above | | 94.1 | Non-compliance | | 94.2 | Defaulter | | 95 | Physician's decision, not specified above | | 96 | Pregnancy | | 96.1 | Pregnancy intended | | 96.2 | Pregnancy ended | | 97 | Study treatment | | 97.1 | Study treatment commenced | | 97.2 | Study treatment completed | | 97.6 | Drug not available | | 98 | Other causes, not specified above | | 99 | Unknown |
| |
| MED_RS2 | Character
See Code ListMED_RS2 | Code | Definition | | 1 | Treatment failure (i.e. virological, immunological, and /or clinical failure) | | 1.1 | Virological failure | | 1.2 | Partial virological failure | | 1.3 | Immunological failure - CD4 drop | | 1.4 | Clinical progression | | 1.5 | Resistance (based on test result) | | 2 | Abnormal fat redistribution | | 3 | Concern of cardiovascular disease | | 3.1 | Dyslipidaemia | | 3.2 | Cardiovascular disease | | 4 | Hypersensitivity reaction | | 5 | Toxicity, predominantly from abdomen/G-I tract | | 5.1 | Toxicity - GI tract | | 5.2 | Toxicity - Liver | | 5.3 | Toxicity - Pancreas | | 6 | Toxicity, predominantly from nervous system | | 6.1 | Toxicity - peripheral neuropathy | | 6.2 | Toxicity - neuropsychiatric | | 6.3 | Toxicity - headache | | 7 | Toxicity, predominantly from kidneys | | 8 | Toxicity, predominantly from endocrine system | | 8.1 | Diabetes | | 9 | Haematological toxicity (anemia, etc.) | | 10 | Hyperlactataemia/lactic acidosis | | 11 | Bone toxicity | | 15 | Social contra-indication | | 16 | Contra-indication unspecified | | 16.8 | Contra-indication expired | | 16.9 | Contra-indication - other | | 17 | MTCT regimen completed | | 70 | Pregnancy - toxicity concerns (during pregnancy) | | 75 | Pregnancy - switch to a more appropriate regimen for PMTCT | | 88 | Death | | 90 | Side effect - any of the above not mentioned | | 90.1 | Comorbidity | | 91 | Toxicity - other (not mentioned above) | | 91.1 | Toxicity - unspecified | | 92 | More effective treatment available | | 92.1 | Simplified treatment available | | 92.2 | Treatment too complex | | 92.3 | Drug interaction | | 92.31 | Drug interaction - commencing TB/BCG treatment | | 92.32 | Drug interaction - ended TB/BCG treatment | | 92.33 | Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available) | | 92.4 | Protocol change | | 92.5 | Regular treatment termination (used in tblMED e.g. for DAAs against HCV, antibiotics) | | 92.6 | End of empiric therapy | | 92.9 | Change in treatment not due to side-effects, failure, poor adherence or contra-indication | | 92.91 | Change to a generic drug | | 92.92 | Change to branded drug | | 93 | Structured Treatment Interruption (STI) | | 93.1 | Structured Treatment Interruption (STI)-at high CD4 | | 94 | Patient's wish/ decision, not specified above | | 94.1 | Non-compliance | | 94.2 | Defaulter | | 95 | Physician's decision, not specified above | | 96 | Pregnancy | | 96.1 | Pregnancy intended | | 96.2 | Pregnancy ended | | 97 | Study treatment | | 97.1 | Study treatment commenced | | 97.2 | Study treatment completed | | 97.6 | Drug not available | | 98 | Other causes, not specified above | | 99 | Unknown |
| Additional reason for stopping drug |
| MED_RS3 | Character
See Code ListMED_RS3 | Code | Definition | | 1 | Treatment failure (i.e. virological, immunological, and /or clinical failure) | | 1.1 | Virological failure | | 1.2 | Partial virological failure | | 1.3 | Immunological failure - CD4 drop | | 1.4 | Clinical progression | | 1.5 | Resistance (based on test result) | | 2 | Abnormal fat redistribution | | 3 | Concern of cardiovascular disease | | 3.1 | Dyslipidaemia | | 3.2 | Cardiovascular disease | | 4 | Hypersensitivity reaction | | 5 | Toxicity, predominantly from abdomen/G-I tract | | 5.1 | Toxicity - GI tract | | 5.2 | Toxicity - Liver | | 5.3 | Toxicity - Pancreas | | 6 | Toxicity, predominantly from nervous system | | 6.1 | Toxicity - peripheral neuropathy | | 6.2 | Toxicity - neuropsychiatric | | 6.3 | Toxicity - headache | | 7 | Toxicity, predominantly from kidneys | | 8 | Toxicity, predominantly from endocrine system | | 8.1 | Diabetes | | 9 | Haematological toxicity (anemia, etc.) | | 10 | Hyperlactataemia/lactic acidosis | | 11 | Bone toxicity | | 15 | Social contra-indication | | 16 | Contra-indication unspecified | | 16.8 | Contra-indication expired | | 16.9 | Contra-indication - other | | 17 | MTCT regimen completed | | 70 | Pregnancy - toxicity concerns (during pregnancy) | | 75 | Pregnancy - switch to a more appropriate regimen for PMTCT | | 88 | Death | | 90 | Side effect - any of the above not mentioned | | 90.1 | Comorbidity | | 91 | Toxicity - other (not mentioned above) | | 91.1 | Toxicity - unspecified | | 92 | More effective treatment available | | 92.1 | Simplified treatment available | | 92.2 | Treatment too complex | | 92.3 | Drug interaction | | 92.31 | Drug interaction - commencing TB/BCG treatment | | 92.32 | Drug interaction - ended TB/BCG treatment | | 92.33 | Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available) | | 92.4 | Protocol change | | 92.5 | Regular treatment termination (used in tblMED e.g. for DAAs against HCV, antibiotics) | | 92.6 | End of empiric therapy | | 92.9 | Change in treatment not due to side-effects, failure, poor adherence or contra-indication | | 92.91 | Change to a generic drug | | 92.92 | Change to branded drug | | 93 | Structured Treatment Interruption (STI) | | 93.1 | Structured Treatment Interruption (STI)-at high CD4 | | 94 | Patient's wish/ decision, not specified above | | 94.1 | Non-compliance | | 94.2 | Defaulter | | 95 | Physician's decision, not specified above | | 96 | Pregnancy | | 96.1 | Pregnancy intended | | 96.2 | Pregnancy ended | | 97 | Study treatment | | 97.1 | Study treatment commenced | | 97.2 | Study treatment completed | | 97.6 | Drug not available | | 98 | Other causes, not specified above | | 99 | Unknown |
| Additional reason for stopping drug Use same list of codes as MED_RS |
| MED_RS4 | Character
See Code ListMED_RS4 | Code | Definition | | 1 | Treatment failure (i.e. virological, immunological, and /or clinical failure) | | 1.1 | Virological failure | | 1.2 | Partial virological failure | | 1.3 | Immunological failure - CD4 drop | | 1.4 | Clinical progression | | 1.5 | Resistance (based on test result) | | 2 | Abnormal fat redistribution | | 3 | Concern of cardiovascular disease | | 3.1 | Dyslipidaemia | | 3.2 | Cardiovascular disease | | 4 | Hypersensitivity reaction | | 5 | Toxicity, predominantly from abdomen/G-I tract | | 5.1 | Toxicity - GI tract | | 5.2 | Toxicity - Liver | | 5.3 | Toxicity - Pancreas | | 6 | Toxicity, predominantly from nervous system | | 6.1 | Toxicity - peripheral neuropathy | | 6.2 | Toxicity - neuropsychiatric | | 6.3 | Toxicity - headache | | 7 | Toxicity, predominantly from kidneys | | 8 | Toxicity, predominantly from endocrine system | | 8.1 | Diabetes | | 9 | Haematological toxicity (anemia, etc.) | | 10 | Hyperlactataemia/lactic acidosis | | 11 | Bone toxicity | | 15 | Social contra-indication | | 16 | Contra-indication unspecified | | 16.8 | Contra-indication expired | | 16.9 | Contra-indication - other | | 17 | MTCT regimen completed | | 70 | Pregnancy - toxicity concerns (during pregnancy) | | 75 | Pregnancy - switch to a more appropriate regimen for PMTCT | | 88 | Death | | 90 | Side effect - any of the above not mentioned | | 90.1 | Comorbidity | | 91 | Toxicity - other (not mentioned above) | | 91.1 | Toxicity - unspecified | | 92 | More effective treatment available | | 92.1 | Simplified treatment available | | 92.2 | Treatment too complex | | 92.3 | Drug interaction | | 92.31 | Drug interaction - commencing TB/BCG treatment | | 92.32 | Drug interaction - ended TB/BCG treatment | | 92.33 | Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available) | | 92.4 | Protocol change | | 92.5 | Regular treatment termination (used in tblMED e.g. for DAAs against HCV, antibiotics) | | 92.6 | End of empiric therapy | | 92.9 | Change in treatment not due to side-effects, failure, poor adherence or contra-indication | | 92.91 | Change to a generic drug | | 92.92 | Change to branded drug | | 93 | Structured Treatment Interruption (STI) | | 93.1 | Structured Treatment Interruption (STI)-at high CD4 | | 94 | Patient's wish/ decision, not specified above | | 94.1 | Non-compliance | | 94.2 | Defaulter | | 95 | Physician's decision, not specified above | | 96 | Pregnancy | | 96.1 | Pregnancy intended | | 96.2 | Pregnancy ended | | 97 | Study treatment | | 97.1 | Study treatment commenced | | 97.2 | Study treatment completed | | 97.6 | Drug not available | | 98 | Other causes, not specified above | | 99 | Unknown |
| Additional reason for stopping drug |
| MEDSTART_RS | Character 1 = Treatment (incl. for presumptive dx)
2 = Prophylaxis (primary or secondary)
9 = Unknown
| Reason for starting medication (optional) |
| MED_DO | Numeric | Dosage (mg or mL) per intake unless MED_FR=-1 (frequency unknown), in which case it means dosage per day (optional) |
| MED_FR | Numeric -1 = Frequency not known
0.33 = 1 dose every third day
0.5 = 1 dose every second day
1 = 1 daily dose/qd
2 = 2 daily doses/bid
3 = 3 daily doses/tid
4 = 4 daily doses
5 = 5 daily doses
6 = 6 daily doses
7 = 7 daily doses
8 = 8 daily doses
9 = 9 daily doses
10 = 10 daily doses
| |
| DOT_Y | Numeric 0 = No
1 = Yes
9 = Unknown
| Directly observed treatment (optional) |